Alle Studien
RekrutierungPhase II und Phase III (Integriert)Interventionell

AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

This study is looking at a new treatment approach for adults with metastatic breast cancer that is HER2-negative or HER2-low. Metastatic means the cancer has spread beyond the breast to other parts of the body. The trial tests an experimental medicine called eftilagimod alpha alongside a standard chemotherapy drug named paclitaxel. Eftilagimod alpha is designed to boost the body's natural immune system to help fight cancer cells more effectively. The first stage of the trial finds the safest, most effective dose. In the main stage, participants receive either the new medicine or a dummy treatment (placebo), together with paclitaxel. Doctors want to find out if this combination helps people live longer and keeps tumours under control, while monitoring safety and quality of life. Taking part is completely voluntary and does not affect your standard care.

Auf einen Blick

Status
Rekrutierung
Phase
Phase II und Phase III (Integriert)
Sponsor
Immutep
Einschreibeziel
99
Starten
24. Juni 2024

Worum geht es in dieser Studie?

Breast cancer cells are routinely tested for a protein called HER2. When tumours have little or none of this protein, they are called HER2-negative or HER2-low. If the cancer spreads to other areas of the body, it is known as secondary or metastatic breast cancer. While standard chemotherapy such as paclitaxel is commonly used to treat this, doctors are continually searching for treatments that can help chemotherapy work better and last longer.

This trial investigates an experimental medicine called eftilagimod alpha. Unlike traditional chemotherapy, which attacks cancer cells directly, eftilagimod alpha is an immunotherapy. It works by alerting and activating your own immune system cells, encouraging them to find and attack the cancer cells alongside the chemotherapy.

The trial is divided into two parts. In the first part, doctors carefully test different dose strengths to find the safest and most effective dose. In the second part, participants are randomly chosen to receive paclitaxel combined with either eftilagimod alpha or a placebo (an inactive substance). This helps researchers prove whether the new medicine makes a genuine difference.

By measuring how long patients live, how well tumours shrink, and how patients feel day-to-day, the research team hopes to discover whether this combination can improve treatment choices and outcomes for people facing advanced breast cancer.

Wichtige Erkenntnisse

  • Tests a new immunotherapy (eftilagimod alpha) alongside standard chemotherapy.
  • Aimed at adults with HER2-negative or HER2-low advanced breast cancer.
  • Designed to check safety, tumour shrinkage, and how long patients live.
  • In the main stage, participants receive either the new drug or a dummy treatment (placebo).
  • Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.

Wer könnte berechtigt sein?

This trial is open to adults aged 18 and over who have been diagnosed with metastatic breast cancer that is HER2-negative or HER2-low. Both women and men can take part, provided their doctor agrees that paclitaxel chemotherapy is an appropriate treatment for them.

Participants must be well enough in their day-to-day lives to attend regular clinic visits and manage standard chemotherapy. The research team will run safety checks before you start, including blood tests, physical checks, and heart traces (ECGs), to confirm it is safe for you to take part.

You may not be eligible if your breast cancer produces high amounts of HER2, or if you have other serious medical conditions that could make taking the study medicines unsafe. The trial doctor will review your full medical records to see if the study is suitable for you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged 18 or older.
  2. I have been diagnosed with metastatic (advanced) breast cancer.
  3. My cancer is confirmed as HER2-negative or HER2-low.
  4. I am able to receive chemotherapy with paclitaxel.
  5. I am well enough to attend regular hospital appointments for tests and scans.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you take part, you will receive standard chemotherapy (paclitaxel), which is given as a drip into a vein. You will also receive either eftilagimod alpha or a placebo, given as an injection under the skin. You will visit the hospital regularly for treatments, blood tests, heart checks, and physical exams. You will also have periodic imaging scans (such as CT scans) to see how your tumour is responding. You will be asked to complete simple questionnaires about your daily symptoms and quality of life. Treatment usually continues for as long as it helps keep the cancer in check and any side effects remain manageable. After finishing treatment, the team will continue to check in on your health.

Potenzielle Risiken und Vorteile

A potential benefit is that the new combination might control your cancer better or help you live longer, although this cannot be guaranteed. Your participation also helps doctors discover better ways to treat breast cancer in the future. However, there are potential risks and side effects. Paclitaxel can cause tiredness, hair loss, sickness, and numbness in the hands or feet. The study drug may cause injection-site redness, flu-like symptoms, or immune reactions. Your health will be monitored very closely throughout the trial. Taking part is entirely voluntary, and you can stop at any time without your regular NHS medical care being affected.

Standorte (2)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Spanien
  • —
    Unbestätigt
    Belgien

Häufige Fragen

What does HER2-negative or HER2-low mean?

HER2 is a protein that can help breast cancer cells grow. If your cancer produces very little or none of this protein, it is described as HER2-low or HER2-negative.

Was ist ein Placebo?

A placebo is a dummy treatment designed to look identical to the real medicine but containing no active ingredients. It helps doctors confirm if the study drug is truly effective.

Will I know if I am receiving the real study drug?

In the Phase 3 part of the trial, neither you nor your doctor will know whether you are receiving eftilagimod alpha or the placebo. This is called a double-blind trial and ensures the results are completely fair.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes. You can leave the clinical trial at any point, for any reason. Your decision will not change your relationship with your medical team or the quality of your care.

Will I still get standard cancer treatment?

Yes. Every participant in this study receives paclitaxel, which is an established, standard chemotherapy treatment for this type of breast cancer.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "AIPAC-003: A randomized, double-blind, placebo-controlled Ph… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.